Drugs / TRX319
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07477639 | Mar 2026 → Aug 2028 expected | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Tr1X, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRX319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07477639 ↗ |
| Modality | Cell therapy | “TRX319 is an investigational research cell therapy” NCT07477639 ↗ |